Slow progression (BP < 130/80 with ACEi/ARB, SGLT2i, finerenone in DKD), control DM, manage complications (anemia, bone-mineral, acidosis), and refer nephrology at eGFR < 30.
Authored pathway active · chronic-kidney-disease.outpatient
Slow progression (BP < 130/80 with ACEi/ARB, SGLT2i, finerenone in DKD), control DM, manage complications (anemia, bone-mineral, acidosis), and refer nephrology at eGFR < 30.
Guidelines: KDIGO 2024 CKD Evaluation and Management · KDIGO 2022 Diabetes in CKD · ACC/AHA 2025 HTN Guideline (BP target < 130/80 in CKD)
Phenotypes (4)
- CKD Stage 1-3a (eGFR > 45 mL/min)
- CKD Stage 3b-4 (eGFR 15-45 mL/min)
- CKD Stage 5 (eGFR < 15 mL/min — Pre-Dialysis)
- CKD from Diabetic Nephropathy
Pathway-scoped symptom and exam intake
Test this pathway's ROS and differential links
Uses LR engine neph.ckd.core.v1, then routes suggested engines into the workspace.
19-panel workspace
chronic-kidney-disease · OutpatientStart patient workup
Open a scratch or linked encounter, add active problems, then keep labs, fluids, acid-base, and electrolyte tools beside the main workspace instead of losing context.
Encounter and problems
No encounter open. Add a problem to create a scratch encounter when none is open.
Multi-window tools
Unified
labs + fluids + acid-base
Labs
fast lab analyzer
Fluid
resuscitation and balance
Electrolytes
Na/K/Mg/Phos/Ca
ABG/VBG
compensation and mixed disorders
Popular entry points
6 quick-startsOr jump straight to the atlas
The Engine Atlas covers every authored disease package with setting chips and pathway badges. Open any engine to load its 19-panel workspace, backed by phenotype-aware reasoning and monitored by the Flow Assistant.